Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
